Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIS-PERIANAL risankizumab study for refractory perianal fistulizing Crohn's disease
jRCTs031260501Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of risankizumab in Crohn's disease and anal fistula, sponsored by AbbVie Inc. Primary endpoint: Composite remission at Week 28. Started Oct 2026; status: recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on jRCTs031260501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260501.